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Cortico-basal ganglia-thalamic (CBT) neural circuits are critical
modulators of cognitive and motor function. When compromised,
these circuits contribute to neurological and psychiatric disorders,
such as Parkinson’s disease (PD). In PD, motor deficits correlate
with the emergence of exaggerated beta frequency (15–30 Hz)
oscillations throughout the CBT network. However, little is known
about how specific cell types within individual CBT brain regions
support the generation, propagation, and interaction of oscillatory
dynamics throughout the CBT circuit or how specific oscillatory
dynamics are related to motor function. Here, we investigated
the role of striatal cholinergic interneurons (SChIs) in generating
beta and gamma oscillations in cortical-striatal circuits and in influ-
encing movement behavior. We found that selective stimulation
of SChIs via optogenetics in normal mice robustly and reversibly
amplified beta and gamma oscillations that are supported by distinct
mechanisms within striatal-cortical circuits. Whereas beta oscillations
are supported robustly in the striatum and all layers of primary
motor cortex (M1) through a muscarinic-receptor mediated mecha-
nism, gamma oscillations are largely restricted to the striatum and
the deeper layers of M1. Finally, SChI activation led to parkinsonian-
like motor deficits in otherwise normal mice. These results highlight
the important role of striatal cholinergic interneurons in supporting
oscillations in the CBT network that are closely related to movement
and parkinsonian motor symptoms.
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Exaggerated beta oscillations (15–30 Hz) within the cortico-basalganglia-thalamic (CBT) neural network are putative electro-
physiological correlates of bradykinesia and rigidity in Parkinson’s
disease (PD) (1–4). Therapies that effectively manage PD motor
symptoms, such as dopamine replacement therapy and deep brain
stimulation, are associated with a suppression of the exaggerated
beta oscillations (4, 5). Beta oscillations are also found in the CBT
circuits of patients with other movement-related disorders, such as
epilepsy and dystonia (6, 7), and in normal, nonhuman primates
(8, 9) and normal rodents (10, 11). Moreover, brief elevations
(≤200 ms) of beta oscillations are observed in the basal ganglia
of task-performing nonhuman primates and rodents during specific
phases of behavioral tasks (10, 12, 13), indicating that beta oscil-
lations may be important for motor and nonmotor functions. In
contrast to the regulated temporal variability of beta oscillations in
normal motor functions, temporal stability is correlated with the
parkinsonian motor symptoms of bradykinesia and rigidity (2).
Together, these findings suggest that brief epochs of beta oscilla-
tions are a normal aspect of basal ganglia dynamics, their temporal
modulation is important for movement regulation, and loss of
regulation or uncontrolled expression of beta oscillations may
contribute to movement deficits, such as those observed in PD.
Despite the clear link between CBT beta oscillations and move-
ment, the mechanisms underlying their generation remain elusive.
Dopamine clearly modulates the generative mechanisms of CBT beta
oscillations and beta frequency coherence between CBT structures. A
hallmark of PD pathology is chronic reduction of dopamine input to
CBT circuits due to midbrain dopaminergic neuron loss. Loss of
midbrain dopamine increases beta oscillation power and co-
herence in PD animal models (14, 15). Similarly, acute reduction
of dopamine locally in the striatum increases striatal beta oscilla-
tions (16). Systemic dopaminergic drugs decrease beta oscillation
power and coherence in PD patients (17), and also increase finely
tuned gamma oscillations in the basal ganglia and thalamus, al-
though we know little about the functional significance of these
finely tuned gamma oscillations in PD (17, 18). Because of the dense
innervation of the striatum by the midbrain dopaminergic system
(19), we have recently proposed that dopamine may modulate basal
ganglia beta oscillations by acting on the striatum, in particular via the
striatal cholinergic system. Dopamine, acting on D2 receptors, pro-
vides tonic suppression of acetylcholine (ACh) release in the striatum
(20). Under conditions of low striatal dopaminergic tone, such as in
PD, increased cholinergic tone may play a more prominent role in
modulating striatal dynamics, such as supporting the generation of
exaggerated beta oscillations (21–23). Additionally, the striatum
contains high levels of cholinergic markers (24), highlighting a
prominent role for cholinergic regulation in striatal function.
Recently, we demonstrated that direct local infusion of the
cholinergic agonist carbachol into the striatum of normal mice
can generate robust beta oscillations within the striatum (23).
Using computational approaches, our previous study predicted
that increased striatal cholinergic tone could lead to elevated
beta oscillations through activation of muscarinic receptors
that lead to the suppression of M current in the striatal medium
spiny neurons. Here, to further demonstrate the function of the
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intrinsic striatal cholinergic system in modulating neural dynam-
ics of the CBT network and the related receptor mechanisms, we
selectively activated striatal cholinergic interneurons (SChIs) by
using optogenetic techniques, while simultaneously recording
local field potentials (LFPs) in the striatum and the primary
motor cortex (M1), with or without local infusion of selective
cholinergic receptor antagonist. We found that brief optogenetic
stimulation of SChIs acutely elevated beta oscillations in the
striatum and all cortical layers of M1, and gamma oscillations in
the striatum and deeper layers of M1. Increased oscillations were
accompanied by increased coherence between striatum and M1
in a layer-dependent manner. In addition, local striatal infusion
of the muscarinic receptor blocker scopolamine, but not the
nicotinic receptor blocker mecamylamine, reduced striatal beta
oscillations. Finally, we assessed the effect of SChI stimulation on
locomotion and found that activation of SChIs decreased move-
ment, increased immobility, and increased rotation. Together,
these results demonstrate that activation of SChIs can generate
elevated beta and gamma oscillations and coherence in the
cortico-striatal network in a cortical layer-dependent manner via
muscarinic receptors, and alter locomotion behavior.
Methods Summary
Technical details are in SI Methods Summary. Briefly, all animal procedures
were approved by the Boston University Institutional Animal Care and Use
Committee (IACUC). Surgically implanted adult mice were recorded awake,
head-fixed. Recordings were made simultaneously in the striatum [stereo-
tactic coordinates 0 anterior-posterior (AP), 2.5–3 medial-lateral (ML), 2–2.5
depth] by using a glass pipette to avoid photoelectric effects during opto-
genetic laser illumination, and in the primary motor cortex (M1) by using
laminar electrodes containing 16 electrode contacts spaced at 100 μm, positioned
across the entire cortical depth (coordinates 1.5–2 AP, 1.25–1.5 ML). To opto-
genetically activate SChIs, a fiber was coupled to a 473-nm laser. All data
analysis was performed in MATLAB. Statistics were performed in MATLAB or
GraphPad Prism.
Results
Selective Optogenetic Activation of SChIs Increased Striatal Alpha,
Beta, and Gamma Oscillations. We recently demonstrated that
the striatal cholinergic system can support the generation of beta
oscillations by using a combination of mathematical modeling
and experimental techniques that combined in vivo electro-
physiology with local infusion of the nonselective cholinergic
agonist carbachol (23). To further explore the ability of intrinsic
SChIs in modulating beta oscillations throughout the CBT net-
work, we recorded LFPs in the striatum and the primary motor
cortex (M1), while optogenetically activating SChIs in transgenic
choline acetyltransferase promoter (Chat)-Channelrhodopsin-2
(ChR2) mice (Fig. 1A). Chat-ChR2 mice were generated by
crossing Chat-Cre mice with Cre-regulated ChR2-reporter mice
(Ai32), resulting in selective ChR2 expression in Chat-positive
SChIs (Fig. 1B). Control groups consisted of Ai32 transgenic
littermates that did not express ChR2 protein because of the lack
of Cre recombinase expression, despite the presence of ChR2
genes in the genome. An optical fiber coupled to a glass electrode
was positioned in the dorsal striatum for simultaneous optogenetic
stimulation and LFP recordings. Glass electrodes were used to
record LFPs at the site of laser illumination to avoid photoelectric
effects that are routinely observed on electrodes made of other
materials (Fig. 1A) (25).
Optogenetic activation of SChIs with a Poisson-distributed
40-Hz laser light pulse train robustly increased oscillations across
broad frequencies in the striatum (Fig. 2 C and D). The increase
in oscillation power persisted for several hundred milliseconds
after laser offset (Fig. 2 C and D), suggesting that direct patterning
of SChIs by laser pulses was unlikely to account for the elevated
oscillations at these frequencies. To further evaluate the changes at
specific frequency bands, we calculated the normalized spectrum
before, during, and after laser stimulation. We found that opto-
genetic stimulation of SChIs robustly increased oscillation power
across higher frequency bands conventionally defined as alpha
(8–15 Hz), beta (15–30 Hz), low gamma (30–60 Hz), and high
gamma (60–100 Hz), but not lower frequency bands of delta (1–
4 Hz) or theta (4–8 Hz) (Fig. 2 E and F; n = 7 mice). A similar
laser illumination protocol in Ai32 control mice failed to alter
oscillation power at any frequency (n = 5 mice, P > 0.05 for all
bands, signed-rank test), confirming that the observed changes in
Chat-ChR2 mice are due to optogenetic activation of SChIs.
To further rule out the possibility that the observed oscilla-
tion changes were due to direct activation of SChIs, we tested a
set of seven additional laser illumination parameters, including
5-s-long constant laser illumination, 1-s-long fixed interval pulse
trains at 50 and 100 Hz, as well as Poisson-distributed pulse
trains at 4, 9, 20, and 40 Hz. Because of the large LFP deflec-
tions induced by optogenetic stimulation of SChIs during the 1-s
stimulation, it was difficult to reliably estimate the power changes
during laser stimulation. Thus, we analyzed the 1-s period immedi-
ately following laser offset. In general, we observed similar increases
in beta and gamma oscillations by using these stimulation patterns
(Figs. S1B and S2; n = 5 mice, P ≤ 0.05, signed-rank test). Together,
these results demonstrate that direct activation of SChIs generates
robust beta and gamma oscillations within the striatum that are
independent of the particular optogenetic stimulation pattern and
persist for an extended period after the offset of light illumination,
suggesting that these oscillations emerge from dynamic network
interactions upon an increase in the striatal cholinergic tone.
SChI Activation Leads to Layer-Dependent Beta and Gamma Oscillation
Changes in the M1. To understand the influence of the oscillations
induced by optogenetic stimulation of SChIs on the rest of the CBT
network, we performed simultaneous recordings in M1 by using a
laminar electrode containing 16 contacts spaced at 100 μm, which
can identify cortical layer-dependent changes (Fig. 3 A and B). We
did not observe laser-induced photoelectric artifacts on the laminar
electrodes in M1. Because they were ∼2 mm away from the striatal
Fig. 1. Experimental setup and protocols. (A) Illustration of the recording configuration. The recording pipette was coupled to an optical fiber and a laminar
probe containing 16 electrode contacts, positioned in the M1. (B) A representative image of the striatum showing ChR2-eYFP fluorescence (green; Left),
immunofluorescence of ChAT (red; Middle), and colocalization (Right).
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laser illumination site, <0.1% of laser light was expected to reach
M1 (25). Optogenetic activation of SChIs in the striatum coincided
with robust LFP voltage deflections across all cortical depths in M1
(Fig. 3B), and oscillation power consistently increased with cortical
depth (Fig. 3C). To compare the difference in LFPs across ana-
tomically defined cortical layers, we averaged the power spectra
recorded at different depths, with the first 500 μm corresponding to
the superficial layers, 500–800 μm corresponding to the middle
layers, and 900–1,200 μm corresponding to the deep layers.
Beta frequency power consistently increased in all M1 layers
during SChI stimulation. In contrast, gamma frequency power,
both high gamma and low gamma, were selectively increased in
the deep layers, but not the superficial layers (Fig. 3 D–F). In the
middle layers, high gamma power was elevated, but not low
gamma power. We observed small but nonsignificant changes in
delta, theta, and alpha frequencies across all layers. Together,
these results provide direct evidence that SChI activation can
enhance beta oscillations in all M1 layers, and gamma oscilla-
tions in a cortical layer-dependent manner. These SChI activation-
induced beta and gamma oscillations across different M1 layers
suggest that beta oscillations can be widely expressed by neu-
ronal ensembles within different M1 cortical layers, whereas gamma
oscillations are selectively expressed in deeper layers, although it is
unknown how different cell types within each M1 layer uniquely
support these oscillations.
SChI Activation Modulates Coherence Between the Striatum and M1.
To evaluate the synchronization of oscillations between the
striatum and M1 upon optogenetic activation of SChIs, we calculated
the coherence of the LFPs recorded in these two structures before
and during laser stimulation. We found an increase in coherence
during laser stimulation between deep layers of M1 and the striatum
at both beta and low gamma frequencies, but not at high gamma
frequencies (Fig. 4; P ≤ 0.05, jackknife test). This increased co-
herence is consistent with the idea that deep M1 layers contribute
to M1-striatal coordination through direct axonal projections.
However, we note that although the coherence at beta frequencies
below 23 Hz is maintained throughout the simulation, coherence at
higher beta frequencies dissipates rapidly after the first second of
stimulation, suggestive of multiple independent beta oscillations
within the 15–30 Hz range defined here.
The lack of coherence changes at high gamma frequencies
suggests that the observed increase in high gamma power may be
due to increased local neuronal activity within M1 (26). In the
middle layer, where both beta and high gamma power increased,
we observed a significant increase in coherence at beta frequency,
but not at high gamma frequencies (Fig. 4). Considering that
middle layers of M1 do not directly connect to the striatum, the
observed increase in coherence at beta frequencies are likely co-
ordinated or relayed through other structures, such as the thalamus
that directly project to the middle layer, especially layer 4. Sur-
prisingly, despite the increase in superficial layer beta power, ac-
tivation of SChIs resulted in significant attenuation of coherence at
beta and gamma frequencies (Fig. 4; P ≤ 0.05, jackknife test),
suggesting that oscillations within the striatum and superficial M1
are independently regulated. In summary, activation of SChIs in
the striatum appears to engage multiple independent beta gener-
ators that interact in the CBT network in a cortical layer-dependent
manner, whereas high gamma oscillations are locally generated.
Striatal Muscarinic Receptors Mediate SChI-Induced Beta and Low
Gamma Oscillations in the Corticostriatal Network. To understand
the receptor mechanism by which SChIs engage the striatum and
M1 to generate beta and gamma oscillations, we combined opto-
genetic activation of SChIs with local intracranial infusion of selective
cholinergic receptor antagonists. We infused either the muscarinic
antagonist scopolamine (100 μg/μL) or the nicotinic antagonist
mecamylamine (10 μg/μL) into the striatum, and optogenetically
activated SChIs while simultaneously recording LFPs in the
striatum and M1.
We observed that scopolamine infusion in the striatum broadly
decreased oscillation power in the striatum across all frequencies
analyzed (approximately from 2 to 100 Hz, Fig. 5A; n = 8 mice; >2
SEM). A similar reduction in oscillation power was also observed
in the middle and deep layers of M1, although not at very low
frequencies of ∼2–5 Hz, (Fig. 5B; n = 8 mice). Interestingly, no
change in power was observed in the superficial layers of M1,
suggesting that oscillatory dynamics in the superficial layers are
only loosely coupled to the CBT network (Fig. 5 B, i). Together
these results demonstrate that intrinsic striatal muscarinic tone is
responsible for basal levels of oscillations across broad frequencies
in the striatum and deeper layers of M1.
We next tested the effectiveness of optogenetic activation of
SChIs in generating oscillations in the presence of muscarinic or
nicotinic receptor blockers. Because of the reduction of oscilla-
tion power across all frequencies upon scopolamine infusion, we
cannot directly compare the effects of optogenetic stimulation in
the presence of scopolamine to that observed in the absence of
scopolamine. We thus compared the effect of optogenetic acti-
vation of SChIs in the presence of scopolamine and found that
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Fig. 2. Optogenetic activation of SChIs increased striatal alpha, beta, and
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activation of SChIs in the presence of the muscarinic blocker
scopolamine remained effective at inducing beta, low gamma,
and high gamma oscillations in the striatum (Fig. 6 B, i and C, i;
P ≤ 0.05, bootstrap test). However, the increases were relatively
weaker compared with that observed without scopolamine (Fig.
6 A, i). In M1, SChI stimulation in the presence of scopolamine
failed to alter beta, low gamma, or high gamma power from the
prestimulation baseline in any cortical layer (Fig. 6 B, ii–iv and C,
ii–iv; P > 0.05, signed-rank test). Infusion of artificial cerebrospinal
fluid (ACSF) or the nicotinic antagonist mecamylamine failed to
alter oscillation power at any frequency in the striatum or M1,
compared with the preinfusion baseline (Fig. 5) (Fig. S3, n = 6
mice infused with mecamylamine; and Fig. S4, n = 5 mice infused
with ACSF; P > 0.05, signed-rank test). Together, these results
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suggest that cholinergically induced elevation of beta and gamma
oscillations in the striatum is mediated by striatal muscarinic receptors,
but not by striatal nicotinic receptors. The fact that in the presence of
scopolamine, SChI activation only elevated striatal oscillations, but not
M1 oscillations, suggests that striatal beta oscillations are independent
of phasic beta input from M1, supporting the existence of a basal
ganglia generator of beta oscillations. These results further suggest
that the elevation inM1 beta oscillations depends on active muscarinic
mechanisms in the striatum.
Unilateral SChI Activation Decreases Locomotion and Increases
Rotation Behavior. To evaluate whether a transient increase in
striatal cholinergic tone is sufficient to alter locomotion, we opto-
genetically stimulated SChIs in another group of freely moving
mice. To optimize the illumination volume, we designed a fiber
array containing four optical fibers unilaterally targeting a large
fraction of the dorsolateral striatum that receives M1 inputs (27)
in Chat-ChR2 mice (n = 5 mice), or control Ai32 mice (n = 5 mice).
We monitored the locomotion in a custom arena while opto-
genetically stimulating SChIs by using the same light illumination
pattern at Poisson-distributed 40 Hz, but illuminated for 2 min to
better quantify behavioral effects (Fig. 7A). Locomotion was mon-
itored for 8 min/d, over 7 consecutive days.
We first estimated the overall effect of stimulating SChIs on
locomotion by calculating the total distance traveled during each
2-min period before, during, and after laser illumination and found
that optogenetic activation of SChIs significantly reduced the total
distance traveled compared with the pre-laser baseline period (Fig.
7 B and C; P ≤ 0.001, Bonferroni-corrected nonparametric paired
signed-rank tests). This reduction persisted for an additional 2 min
immediately after laser offset (post-laser 1) (P ≤ 0.001, paired
signed-rank test) and returned to baseline in the subsequent 2-min
interval (Post-Laser 2) (P > 0.05, paired signed-rank test). Further
analysis indicated that locomotion reduction resulted from in-
creased immobility, defined as the percentage of time when
movement was smaller than 1.5 cm/s (Fig. 7D; P ≤ 0.001, paired
signed-rank test), as well as decreased movement speed (Fig. 7E;
P ≤ 0.001, paired signed-rank test). The same optogenetic analysis
in control Ai32 mice did not produce any change in locomotion,
immobility, or movement speed (n = 5, P > 0.05 for all periods
analyzed, paired signed-rank test), confirming that the observed
locomotion deficit was due to optogenetic activation of SChIs.
To further assess whether unilateral optogenetic stimulation
of SChIs biases movement direction preference, we assessed
rotation behavior. Interestingly, we found that stimulation of SChIs
in one hemisphere resulted in a significant increase in both ipsi-
lateral and contralateral rotations during the laser period (Fig. 7F;
P ≤ 0.01 and P ≤ 0.05, respectively, paired signed-rank test). Similar
analysis in control Ai32 mice did not yield any change in rotation
behavior (P > 0.05, paired signed-rank tests). In the context of our
experimental protocol, these results suggest that optogenetic acti-
vation of SChIs is not sufficient to bias movement direction pref-
erence in freely moving mice, but instead leads to an overall
increase in rotation behavior. In summary, our results suggest that
SChIs are critically involved in modulating locomotion, and that a
selective increase in striatal cholinergic tone leads to direct motor
behavioral deficits.
Discussion
We tested the role of intrinsic physiological striatal ACh release
in modulating beta and gamma oscillations within cortico-striatal
circuits. Combining optogenetics, pharmacology, electrophysiol-
ogy, and behavioral assays in mice, we show that SChI activation
reliably and reversibly increased alpha, beta, and gamma oscil-
lations in the striatum. In M1, SChI stimulation increased beta
power in all layers and gamma power in a layer-dependent
manner. SChI-induced striatal and M1 beta and low gamma
oscillations critically depended on striatal muscarinic receptors.
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Furthermore, SChI activation correlated with decreased loco-
motion and increased rotation behavior. Together, these results
demonstrate that SChIs mediate changes in beta and gamma
oscillations within the CBT circuit that are relevant to movement
and movement deficits.
Activation of SChIs selectively increased higher frequency
oscillations in the striatum, including alpha, beta, and gamma
oscillations, but not lower frequency theta or delta oscillations.
In our previous work, we found beta oscillations were elevated in
striatum in response to the local infusion of the cholinergic ag-
onist, carbachol (23). However, this study did not look at gamma
oscillations and, thus, more work is needed to determine whether
carbachol also elevates gamma frequency rhythms in striatum. In
M1, SChI activation increased beta oscillations in all layers, and
gamma oscillations only in middle and deep layers. Interestingly,
despite the increase in beta, low gamma, and high gamma os-
cillations in the striatum and M1 deeper layers, the coherence
between these two structures remained unchanged at high
gamma frequencies during SChI activation, further confirming
that these oscillations are supported by distinct mechanisms, with
high gamma oscilations likely representing a local increase in
neuronal excitability (26). Using conventionally defined fre-
quency bands, we find SChI stimulation increased alpha oscil-
lations (8–15 Hz) in striatum but not in M1. Interestingly, the PD
motor symptoms of bradykinesia and rigidity are correlated with
elevated beta oscillations in basal ganglia that can extend down
to 8 Hz and, thus, includes the alpha frequency range (4, 28).
To determine the contributions of cholinergic receptor sub-
types toward beta oscillation generation, we incorporated phar-
macological techniques into our present study. Local infusion of
scopolamine, a muscarinic receptor antagonist, in the striatum not
only reduced oscillation powers across all frequencies analyzed, but
also drastically reduced the evoked beta and gamma oscillations
upon optogenetic stimulation of SChIs.
In contrast, scopolamine did not alter SChI-induced high
gamma oscillations, suggesting a mechanistic separation between
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the generators of beta/low gamma and high gamma oscillations. In
contrast, the nicotinic receptor antagonist mecamylamine failed to
change SChI-induced elevation of beta, low gamma, or high gamma
oscillations in either the striatum or M1. These results demonstrate
that SChIs exert rapid and powerful control over the dynamic
generation of beta and gamma oscillations both within the striatum
and throughout the CBT network through muscarinic mechanisms.
Beta frequency oscillations are found in the basal ganglia and the
cortex of PD patients (29, 30) and PD animal models (15, 29, 31).
Beta elevation correlates with the PD motor symptoms of brady-
kinesia and rigidity. The multiple plastic changes seen throughout
the CBT loop due to chronic loss of dopamine are not present in
our current experiments, and we do not consider the SChI stimu-
lation state equivalent to the parkinsonian state. Indeed SChI
stimulation-induced gamma oscillations and contralateral rotational
behavior are not observed in parkinsonian states. Nevertheless, it is
interesting that some parkinsonian phenomenology (elevated beta
and hypokinetic movement) was evident during SChI stimulation
despite normal dopaminergic function and lack of parkinsonian
plastic changes. Interestingly, one recent study demonstrated that
optogenetic inhibition of SChIs alleviated some parkinsonian motor
symptoms in 6-hydroxydopamine (6-OHDA) mice (32). Together,
these findings suggest that the CBT network components that
modulate beta oscillations in normal states may be opera-
tional, but unmodulated, in PD states.
Striatal manipulations often produce alterations in behavior
that generally can be classified as either hyperkinetic or hypokinetic.
Examples of striatal perturbations resulting in hyperkinesia include
inhibition of striatal fast spiking (FS) interneurons (33), optogenetic
stimulation of D1 medium spiny neurons (MSNs) (34), and intra-
striatal infusion of amphetamine (35). In contrast, hypokinetic
movements are produced by optogenetic stimulation of striatal D2
MSNs (34). Here, we demonstrated that stimulation of SChIs also
resulted in hypokinetic movements, highlighting a prominent role
of SChIs in modulating basal ganglia network dynamics. We note
that a recent study reported a lack of movement changes upon
optogenetic simulation of SChIs in virally labeled animals (32). It
is possible that sufficient activation of SChIs is needed to pro-
duce an observable behavioral effect, and our experimental
conditions using transgenic mice may allow us to activate suf-
ficient numbers of SChIs to bias behavior.
Interestingly, we observed unexpected changes in rotational
behavior in both directions after unilateral SChI stimulation. It is
possible that unilateral stimulation of SChIs could engage not
only the ipsilateral CBT loop but also the contralateral CBT loop
through M1 bilaterally projecting intratelencephalic neurons (36).
Alternatively, because both ACh and glutamate are released from
SChIs (37) and can potentially activate both D1 and D2 pop-
ulations of MSNs, it is also possible that the direction of rotation
depends on the relative excitation level of these two populations.
Although the source of the exaggerated beta oscillations in PD
has not yet been established, we suggest here that it may consist
of multiple, interacting sources. At least two independent beta
generators are suggested by the distinct time course of coherence
between deep layers of M1 and the striatum upon SChI activa-
tion, with coherence at higher beta frequencies of ∼22–30 Hz
increasing and then rapidly dissipating, and coherence at lower
beta frequencies of ∼15–22 Hz staying elevated throughout SChI
activation. The dissipating coherence in the high beta frequency
range despite consistently elevated beta power suggests at least
two independent sources of high frequency beta, possibly one
from basal ganglia networks and another in M1. An independent
beta generator in M1 is consistent with in vitro work, demon-
strating that deep layers of M1 can generate high frequency beta
oscillations (∼27 Hz) in layer V in the presence of carbachol and
kainate (38). Additionally, we observed decreased coherence
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between striatum and superficial M1 throughout the entire beta
frequency range (15–30 Hz) despite significant increases in beta
power in these structures upon SChI stimulation, suggesting an
additional source of beta oscillations within the CBT loop. It has
been observed that both high and low frequency beta oscillations
are elevated in the basal ganglia in parkinsonian states and are
correlated with different PD motor symptoms (39). The observed
dissociation of different frequency beta oscillations here, in
normal mice with elevated striatal cholinergic tone, may indicate
possible distinct network sources that generate PD-related beta-
band oscillations.
Whereas the literature proposes several putative mechanisms of
CBT loop beta oscillation generation, our previous work suggests
that networks of striatal MSNs can produce beta oscillations with
sufficient MSN excitation (23). Because muscarinic receptors can
increase MSN excitability by decreasing the M-current, our com-
putational model predicts that muscarinic receptor blockade will
interfere with the beta-producing mechanism in the striatum. This
mechanism is supported by the experimental results of the present
study demonstrating that striatal muscarinic blockade significantly
decreases SChI stimulation-induced beta oscillations in the stria-
tum. If the beta-producing mechanism of high striatal cholinergic
tone plays a role in PD, our work suggests that modalities reducing
striatal cholinergic tone may be instrumental in alleviating exces-
sive beta oscillations in the parkinsonian CBT loop, along with
their correlated motor symptoms. In fact, systemic antimuscarinic
drugs were the sole pharmacologic treatment for PD until the late
1960s, when L-dopa was introduced (40), although their clinical use
is limited by neuropsychiatric and cognitive side effects (41).
The literature proposes two other origins of pathologic beta
oscillations in PD: the subthalamic nucleus (STN)-globus pal-
lidus externa (GPe) circuit (42) and M1 (38). The former hy-
pothesis depends on the presence of plastic changes attributable
to chronic loss of dopamine in the STN-GPe network. Such
mechanisms may be applicable to the parkinsonian state. How-
ever, our results suggest that neither chronic plastic changes nor
chronic low dopamine is needed to produce robust beta oscil-
lations within the CBT loop upon SChI stimulation. We note
that a similar finding is evident in M1, where robust beta oscil-
lations can emerge in nonparkinsonian M1 slices in the presence
of sufficient excitation with carbachol and kainate (38, 43). Ex-
citation of M1 neurons occurs in response to increased D1 MSN
spiking and can also occur transiently to a subset of M1 neurons
in response to D2 MSN spiking (44). To what extent M1 gen-
erated beta oscillations are induced under the conditions of SChI
stimulation is an interesting topic of future study. Excitation to
M1 during SChI stimulation may depend on the amount and
timing of excitation provided to D1 versus D2 MSNs (44).
Recent studies (45, 46) showed that microinfusions of
GABAergic antagonists in GPe failed to reduce beta oscillatory
activities at the site of infusion in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) neurotoxin-induced Parkinsonian
monkeys, although infusion of glutamatergic antagonists in GPe
and STN reduced beta oscillations. These results are consistent
with the view that the striatum is a source of beta oscillations,
whereas the STN-GPe network serves as an amplifier of the
striatally generated oscillations. In our framework, mechanisms
that decrease the activity of STN or GPe will compromise the
beta amplification mechanism and, thus, decrease beta oscilla-
tions. Correspondingly, mechanisms that increase the connec-
tivity of STN and GPe (e.g., suppression of GPe lateral inhibition
with GABAergic antagonist) may increase beta oscillations. This
observation, taken together with the fact that microinfusion of
GABAergic antagonists blocks a small amount of striatal inputs
to GPe, suggests that substantial change to GPe beta oscillatory
activity would not be expected with the microinfusion experi-
ments performed in refs. 45 and 46.
Although much of the oscillatory spectrum in striatum is ele-
vated during SChI stimulation, these elevations do not occur
across the entire frequency range and, thus, are not considered a
broadband increase in power. In contrast, scopolamine infusion
decreased power at all frequencies, as expected with a broad-
band decrease (Fig. 5A). However, in the presence of scopol-
amine, SChIs remained as effective as in the absence of
scopolomine in elevating high gamma oscillations, but not beta
or low gamma, suggesting a mechanistic separation between the
generators of these frequencies. Additionally, coherence be-
tween striatum and the deep layers of M1 increased for beta and
low gamma, but not high gamma, despite increases in power in
both structures in all these frequency bands. Thus, beta and low
gamma elevations appear to be both selectively elevated and
coordinated in the CBT circuit during SChI stimulation, whereas
high gamma may represent increased neuronal excitability (26).
SChI activation also produced electrophysiological effects that
are not commonly observed in PD, including gamma power (30–
100 Hz) elevation in cortex and striatum. Finely tuned gamma
oscillations in the range of 60–90 Hz are a consistent feature of
basal ganglia and thalamic recordings (47) that are diminished in
PD patients in the absence of dopaminergic replacement (17,
18). However, rather than an increase in finely tuned gamma,
here we observed a broader-band gamma power increase, which
may represent a general increase in neuronal activity (26). Laser-
induced striatal high gamma oscillations remained elevated after
either muscarinic or nicotinic blockade, suggesting that ACh is
not involved in the generation of striatal high gamma oscilla-
tions. Glutamate, which is also coreleased from SChIs, may be
responsible for the increase in high gamma oscillations during
SChI stimulation (37). Striatal low gamma oscillations, however,
are more correlated with beta in our current study, consistent
with that observed in the basal ganglia of rats (10). While it is
unclear how low gamma is generated in the CBT circuits, evi-
dence from the ventral striatum of rats have suggested that low
and high gamma have distinct sources, with dopaminergic drugs
selectively diminishing the power of low gamma and enhancing
the power of high gamma (48). In addition, low and high gamma
oscillations are increased at different times during a spatial de-
cision task (49), likely coordinated by different sets of FS inter-
neurons (48, 49). Further work is required to delineate the
mechanisms that result in increased M1 low and high gamma
oscillatory activity due to increased striatal cholinergic tone.
Interneurons represent a small proportion of striatum, but these
neurons can strongly modulate striatal output. The proportion of
interneurons in striatum is 4–5% in mouse, >23% in monkey (50),
and up to at least 25% in human (50), suggesting a more prom-
inent role for striatal interneurons in nonhuman primates and
humans. The majority of GABAergic interneurons in the striatum
are parvalbumin-positive FS interneurons, which project primarily
to the MSNs. Although FS interneurons are excited by nicotinic
agonists (51), optogenetic activation of SChIs failed to increase FS
interneuron spiking in one study (52). Additionally, optogenetic
stimulation of SChIs in ChAT-ChR2 mice elicits both fast and
slow inhibitory postsynaptic potentials in MSNs by nicotinic-me-
diated GABA release from dopamine projections to striatum (53)
and neuropeptide Y-expressing neurogliaform GABAergic inter-
neurons, resulting in inhibition of MSNs (52). However, nicotinic
receptors generally quickly desensitize and, thus, we did not ex-
pect GABAergic blockade of MSN spiking to continue through
the 5 s of stimulation used in our current study. Accordingly, our
study reveals that nicotinic receptor blockade by mecamylamine
did not change the spectral profile of either beta or gamma
oscillations in the striatum or cortex over 5-s periods. This
result suggests that SChI-induced GABA release does not exert
long-term control over the SChI-induced oscillations along the
corticostriatal circuit.
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In contrast, we show that SChI-induced elevation of beta and
low gamma oscillations depends on muscarinic receptors, because
striatal scopolamine infusion lowered SChI-induced spectral
power elevations of these oscillations. ACh acts through musca-
rinic receptors present on MSNs to decrease the activity of KCNQ
(M-current) and Kir2.3 channels, thereby increasing MSN excit-
ability (54, 55). In addition, ACh also works through muscarinic
receptors to inhibit the release of glutamate from corticostriatal
terminals and GABA from striatal FS cells (51, 56). Thus, mus-
carinic receptor activity diminishes the impact of glutamatergic
and GABAergic input on MSNs while simultaneously increasing
the excitability of MSNs. Therefore, muscarinic receptor activa-
tion could potentially accentuate the intrinsic dynamics of the
MSN network.
It is surprising that stimulation of a single interneuron type,
SChIs, can reversibly reproduce some of the key electrophysiolog-
ical and behavioral manifestations of PD in normal mice, including
increased beta oscillations in corticostriatal circuits, increased co-
herence between the cortex and the basal ganglia, and decreased
mobility. SChI stimulation also increased rotational behavior, a
phenotype often observed in mice rendered parkinsonian by a
6-OHDA lesion (57). These results suggest that the exaggerated
beta oscillations in PD may reflect an uncontrolled expression of a
normal dynamical state of the CBT network, a state that is directly
modulated by SChI excitability.
In summary, we provide evidence supporting the existence of a
beta frequency pacemaker within the CBT loop that can be ac-
tivated by stimulation of striatal cholinergic interneurons via
striatal muscarinic receptors. Combined with our findings of
behavioral deficits similar to those in PD upon stimulating this
pacemaker, our results suggest that the beta oscillations in PD
may be an overexpression of normal CBT network dynamics due
to a striatal dopamine/ACh imbalance, rather than a de novo
oscillation due to a PD-induced network pathology.
ACKNOWLEDGMENTS. We thank Kimberley H. Ching for assistance with im-
munocytochemistry and illustration of recording configuration, Moona
Abdulkerim for assistance with behavioral experiments, members of the X.H.
laboratory and N.K. laboratory for various technical support and sugges-
tions over the course of the study, and our reviewers for their helpful com-
ments and suggestions. X.H. acknowledges funding from NIH Director’s
New Innovator Award 1DP2NS082126, NINDS Grant 1R21NS078660, Pew Foun-
dation, Alfred P. Sloan Foundation, Boston University Biomedical Engineering
Department, and Boston University Photonic Center. X.H. and M.M.M
acknowledge CRCNS NIH Grant 1R01NS081716, and N.K. acknowledges
NSF DMS-1042134-5.
1. Brown P (2007) Abnormal oscillatory synchronisation in the motor system leads to
impaired movement. Curr Opin Neurobiol 17(6):656–664.
2. Little S, Pogosyan A, Kuhn AA, Brown P (2012) β band stability over time correlates
with Parkinsonian rigidity and bradykinesia. Exp Neurol 236(2):383–388.
3. Brown P, Williams D (2005) Basal ganglia local field potential activity: Character and
functional significance in the human. Clinical Neurophysiol 116(11):2510–2519.
4. Kühn AA, Kupsch A, Schneider GH, Brown P (2006) Reduction in subthalamic 8-35 Hz
oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur J
Neurosci 23(7):1956–1960.
5. Kühn AA, et al. (2008) High-frequency stimulation of the subthalamic nucleus sup-
presses oscillatory beta activity in patients with Parkinson’s disease in parallel with
improvement in motor performance. J Neurosci 28(24):6165–6173.
6. Herrojo Ruiz M, Brücke C, Nikulin VV, Schneider GH, Kühn AA (2014) Beta-band
amplitude oscillations in the human internal globus pallidus support the encoding of
sequence boundaries during initial sensorimotor sequence learning. Neuroimage
85(Pt 2):779–793.
7. Sochurkova D, Rektor I (2003) Event-related desynchronization/synchronization in the
putamen. An SEEG case study. Exp Brain Res 149(3):401–404.
8. Bartolo R, Merchant H (2015) β oscillations are linked to the initiation of sensory-cued
movement sequences and the internal guidance of regular tapping in the monkey.
J Neurosci 35(11):4635–4640.
9. Courtemanche R, Fujii N, Graybiel AM (2003) Synchronous, focally modulated beta-
band oscillations characterize local field potential activity in the striatum of awake
behaving monkeys. J Neurosci 23(37):11741–11752.
10. Leventhal DK, et al. (2012) Basal ganglia beta oscillations accompany cue utilization.
Neuron 73(3):523–536.
11. Berke JD, Okatan M, Skurski J, Eichenbaum HB (2004) Oscillatory entrainment of
striatal neurons in freely moving rats. Neuron 43(6):883–896.
12. Feingold J, Gibson DJ, DePasquale B, Graybiel AM (2015) Bursts of beta oscillation
differentiate postperformance activity in the striatum and motor cortex of monkeys
performing movement tasks. Proc Natl Acad Sci USA 112(44):13687–13692.
13. Schmidt R, Leventhal DK, Mallet N, Chen F, Berke JD (2013) Canceling actions involves
a race between basal ganglia pathways. Nat Neurosci 16(8):1118–1124.
14. Sharott A, et al. (2005) Dopamine depletion increases the power and coherence of
beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. Eur
J Neurosci 21(5):1413–1422.
15. Mallet N, et al. (2008) Disrupted dopamine transmission and the emergence of ex-
aggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci
28(18):4795–4806.
16. Costa RM, et al. (2006) Rapid alterations in corticostriatal ensemble coordination
during acute dopamine-dependent motor dysfunction. Neuron 52(2):359–369.
17. Brown P, et al. (2001) Dopamine dependency of oscillations between subthalamic
nucleus and pallidum in Parkinson’s disease. J Neurosci 21(3):1033–1038.
18. Kempf F, et al. (2009) Gamma activity and reactivity in human thalamic local field
potentials. Eur J Neurosci 29(5):943–953.
19. Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine.
Annu Rev Neurosci 34:441–466.
20. DeBoer P, Heeringa MJ, Abercrombie ED (1996) Spontaneous release of acetylcholine
in striatum is preferentially regulated by inhibitory dopamine D2 receptors. Eur J
Pharmacol 317(2–3):257–262.
21. Ikarashi Y, Takahashi A, Ishimaru H, Arai T, Maruyama Y (1997) Regulation of do-
pamine D1 and D2 receptors on striatal acetylcholine release in rats. Brain Res Bull
43(1):107–115.
22. Ding J, et al. (2006) RGS4-dependent attenuation of M4 autoreceptor function in
striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 9(6):
832–842.
23. McCarthy MM, et al. (2011) Striatal origin of the pathologic beta oscillations in Par-
kinson’s disease. Proc Natl Acad Sci USA 108(28):11620–11625.
24. Pisani A, Bernardi G, Ding J, Surmeier DJ (2007) Re-emergence of striatal cholinergic
interneurons in movement disorders. Trends Neurosci 30(10):545–553.
25. Han X, et al. (2009) Millisecond-timescale optical control of neural dynamics in the
nonhuman primate brain. Neuron 62(2):191–198.
26. Manning JR, Jacobs J, Fried I, Kahana MJ (2009) Broadband shifts in local field po-
tential power spectra are correlated with single-neuron spiking in humans. J Neurosci
29(43):13613–13620.
27. Ramanathan S, Hanley JJ, Deniau JM, Bolam JP (2002) Synaptic convergence of motor
and somatosensory cortical afferents onto GABAergic interneurons in the rat stria-
tum. J Neurosci 22(18):8158–8169.
28. Kühn AA, et al. (2009) Pathological synchronisation in the subthalamic nucleus of
patients with Parkinson’s disease relates to both bradykinesia and rigidity. Exp Neurol
215(2):380–387.
29. Stein E, Bar-Gad I (2013) β oscillations in the cortico-basal ganglia loop during par-
kinsonism. Exp Neurol 245:52–59.
30. Pollok B, et al. (2012) Motor-cortical oscillations in early stages of Parkinson’s disease.
J Physiol 590(13):3203–3212.
31. Devergnas A, Pittard D, Bliwise D, Wichmann T (2014) Relationship between oscilla-
tory activity in the cortico-basal ganglia network and parkinsonism in MPTP-treated
monkeys. Neurobiol Dis 68:156–166.
32. Maurice N, et al. (2015) Striatal cholinergic interneurons control motor behavior and
basal ganglia function in experimental parkinsonism. Cell Reports 13(4):657–666.
33. Gittis AH, et al. (2011) Selective inhibition of striatal fast-spiking interneurons causes
dyskinesias. J Neurosci 31(44):15727–15731.
34. Kravitz AV, et al. (2010) Regulation of parkinsonian motor behaviours by optogenetic
control of basal ganglia circuitry. Nature 466(7306):622–626.
35. Wang Z, Rebec GV (1993) Neuronal and behavioral correlates of intrastriatal infusions
of amphetamine in freely moving rats. Brain Res 627(1):79–88.
36. Shepherd GM (2013) Corticostriatal connectivity and its role in disease. Nat Rev
Neurosci 14(4):278–291.
37. Higley MJ, et al. (2011) Cholinergic interneurons mediate fast VGluT3-dependent
glutamatergic transmission in the striatum. PLoS One 6(4):e19155.
38. Yamawaki N, Stanford IM, Hall SD, Woodhall GL (2008) Pharmacologically induced
and stimulus evoked rhythmic neuronal oscillatory activity in the primary motor
cortex in vitro. Neuroscience 151(2):386–395.
39. Toledo JB, et al. (2014) High beta activity in the subthalamic nucleus and freezing of
gait in Parkinson’s disease. Neurobiol Dis 64:60–65.
40. Fox SH (2013) Non-dopaminergic treatments for motor control in Parkinson’s disease.
Drugs 73(13):1405–1415.
41. Katzenschlager R, Sampaio C, Costa J, Lees A (2003) Anticholinergics for symptomatic
management of Parkinson’s disease. Cochrane Database Syst Rev (2):CD003735.
42. Holgado AJ, Terry JR, Bogacz R (2010) Conditions for the generation of beta oscillations
in the subthalamic nucleus-globus pallidus network. J Neurosci 30(37):12340–12352.
43. Lacey MG, et al. (2014) Spike firing and IPSPs in layer V pyramidal neurons during beta
oscillations in rat primary motor cortex (M1) in vitro. PLoS One 9(1):e85109.
44. Oldenburg IA, Sabatini BL (2015) Antagonistic but not symmetric regulation of pri-
mary motor cortex by basal ganglia direct and indirect pathways. Neuron 86(5):
1174–1181.
45. Bar-Gad I, Elias S, Vaadia E, Bergman H (2004) Complex locking rather than complete
cessation of neuronal activity in the globus pallidus of a 1-methyl-4-phenyl-1,2,3,6-
Kondabolu et al. PNAS | Published online May 16, 2016 | E3167
N
EU
RO
SC
IE
N
CE
PN
A
S
PL
U
S
tetrahydropyridine-treated primate in response to pallidal microstimulation. J Neurosci
24(33):7410–7419.
46. Tachibana Y, Iwamuro H, Kita H, Takada M, Nambu A (2011) Subthalamo-pallidal
interactions underlying parkinsonian neuronal oscillations in the primate basal gan-
glia. Eur J Neurosci 34(9):1470–1484.
47. Jenkinson N, Kühn AA, Brown P (2013) γ oscillations in the human basal ganglia. Exp
Neurol 245:72–76.
48. Berke JD (2009) Fast oscillations in cortical-striatal networks switch frequency fol-
lowing rewarding events and stimulant drugs. Eur J Neurosci 30(5):848–859.
49. van der Meer MA, Redish AD (2009) Low and high gamma oscillations in rat ventral
striatum have distinct relationships to behavior, reward, and spiking activity on a
learned spatial decision task. Front Integr Nuerosci 3:9.
50. Graveland GA, Williams RS, DiFiglia M (1985) A Golgi study of the human neo-
striatum: Neurons and afferent fibers. J Comp Neurol 234(3):317–333.
51. Koós T, Tepper JM (2002) Dual cholinergic control of fast-spiking interneurons in the
neostriatum. J Neurosci 22(2):529–535.
52. English DF, et al. (2011) GABAergic circuits mediate the reinforcement-related signals
of striatal cholinergic interneurons. Nat Neurosci 15(1):123–130.
53. Nelson AB, et al. (2014) Striatal cholinergic interneurons Drive GABA release from
dopamine terminals. Neuron 82(1):63–70.
54. Shen W, Hamilton SE, Nathanson NM, Surmeier DJ (2005) Cholinergic suppression of
KCNQ channel currents enhances excitability of striatal medium spiny neurons.
J Neurosci 25(32):7449–7458.
55. Shen W, et al. (2007) Cholinergic modulation of Kir2 channels selectively elevates
dendritic excitability in striatopallidal neurons. Nat Neurosci 10(11):1458–1466.
56. Higley MJ, Soler-Llavina GJ, Sabatini BL (2009) Cholinergic modulation of multi-
vesicular release regulates striatal synaptic potency and integration. Nat Neurosci
12(9):1121–1128.
57. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson’s disease in rats: An
evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175(2):
303–317.
58. Madisen L, et al. (2012) A toolbox of Cre-dependent optogenetic transgenic mice for
light-induced activation and silencing. Nat Neurosci 15(5):793–802.
59. Bokil H, Andrews P, Kulkarni JE, Mehta S, Mitra PP (2010) Chronux: A platform for
analyzing neural signals. J Neurosci Methods 192(1):146–151.
E3168 | www.pnas.org/cgi/doi/10.1073/pnas.1605658113 Kondabolu et al.
